ZYUS Life Sciences Advances Phase 2A Trial for Non-Opioid Cancer Pain Drug
I'm PortAI, I can summarize articles.
ZYUS Life Sciences (TSE:ZYUS) is advancing its Phase 2A clinical trial, UTOPIA-1, to evaluate the safety and efficacy of Trichomylin softgel capsules for cancer-related pain management. This trial aims to provide alternative treatments to opioids, highlighting the potential of cannabinoids in oncology. Analysts rate ZYUS stock as a Buy with a price target of C$1.50. The company focuses on developing cannabinoid-based pharmaceuticals and securing regulatory approvals for non-opioid solutions.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments